Asitri Dashboard

Search Clinical Trials

The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.

Saved Searches

Choose Search
Basic Search
Targeted Search

Clinical Trials Search Results

Search History:
Count: 75
Selected: 0
NCT IDTitle
NCT03644303Targeted Radiotherapy in Androgen-suppressed Prostate Cancer Patients.
NCT01379742Comparison of Between ThinSeed™ and OncoSeed™ for Permanent Prostate Brachytherapy
NCT02470936Web-based Lifestyle Trial Among Men With Prostate Cancer: Prostate 8
NCT03007732Pembrolizumab +/- SD-101 in Hormone-Naïve Oligometastatic Prostate Cancer With RT and iADT
NCT05918263Exercise for Tumor Suppressive Impact in Black Men With Prostate Cancer on Active Surveillance: The REMOVE Trial
NCT06059118Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer
NCT06046040TmPSMA-02 in mCRPC
NCT02269982Prospective CiRculating prOstate Cancer Predictors in HighEr Risk mCRPC studY
NCT06040125Debunking the Frailty-sarcopenIa-ADT Axis in mEtastatic Prostate canceR With multiComponent Exercise: The FIERCE Trial
NCT06200974Multi-omic Approach to Study HDR Brachytherapy for Favorable Risk and Low Tier Intermediate Risk Prostate Cancer
NCT07002320Investigating SX-682 in Combination With Apalutamide in Metastatic Castration-resistant Prostate Cancer
NCT05445609Vidutolimod (CMP-001) in Combination With Nivolumab for the Treatment of Metastatic Castration Resistant Prostate Cancer
NCT05320406RElugolix VErsus LeUprolide Cardiac Trial
NCT02080650Characterization of Circulating Tumor Cells Captured by c-MET (CTC-MET)
NCT02445976Once-daily Oral Seviteronel in Patients With Castration-Resistant Prostate Cancer Progressing on Enzalutamide or Abiraterone.
NCT07050433COMPASS Study for Metastatic Castration-resistant Prostate Cancer
NCT01990196Neoadjuvant Phase 2 Study Comparing the Effects of AR Inhibition With/Without SRC or MEK Inhibition in Prostate Cancer
NCT04116775Fecal Microbiota Transplant and Pembrolizumab for Men With Metastatic Castration Resistant Prostate Cancer.
NCT06449664Training for Men Undergoing Androgen Deprivation Therapy.
NCT00156884A Trial of Strontium +/- Cisplatin for the Palliation of Bone Pain Secondary to Hormone Refractory Prostate Cancer
NCT02735252PROMOTE: Identifying Predictive Markers of Response for Genitourinary Cancer
NCT03492424Ablative Therapy in the Management of Prostate Cancer
NCT02499835Vaccine Therapy and Pembrolizumab in Treating Patients With Hormone-Resistant, Metastatic Prostate Cancer
NCT03392428A Trial of 177Lu-PSMA617 Theranostic Versus Cabazitaxel in Progressive Metastatic Castration Resistant Prostate Cancer
NCT02159690A Phase II Neoadjuvant Study of Enzalutamide, Abiraterone Acetate, Dutasteride and Degarelix in Men With Localized Prostate Cancer Pre-prostatectomy
NCT03031821Metformin in Patients Initiating ADT as Prevention and Intervention of Metabolic Syndrome
NCT04447703Technology-Enhanced Acceleration of Germline Evaluation for Therapy, TARGET Study
NCT03358563Pilot Trial of Chemohormonal Therapy Followed by Prostatectomy in High Risk Prostate Cancer
NCT02985021Docetaxel and Carboplatin for Patients With mCRPC and DNA-Repair Deficiencies
NCT04824937Telaglenastat + Talazoparib In Prostate Cancer
NCT00651222Influence of Hormone Therapy on Heart Attack Incidence in Men Undergoing Prostate Brachytherapy
NCT00744549Study of Antioxidants on MRI Detectable Early Stage Prostate Cancer Among Men on Active Surveillance
NCT02478125Pilot Study of Mobilization and Treatment of Disseminated Tumor Cells in Men With Metastatic Prostate Cancer
NCT05355727PROSAIC-DS Study (PROState AI in Cancer - Decision Support)
NCT0471672568Ga-PSMA-11 PET for the Diagnosis of Metastatic Castration Resistant Prostate Cancer
NCT02677376Imaging Biomarkers to Validate Response in Enzalutamide-Treated mCRPC
NCT02881242Trametinib in Treating Patients With Progressive Metastatic Hormone-Resistant Prostate Cancer
NCT02856100Comparison of PSMA-based 18F-DCFPyL PET/CT to Conventional Imaging in the Evaluation of Patients With Castration-Resistant Prostate Cancer
NCT05041504A Web-based Peer Navigation Program for Men With Prostate Cancer
NCT01289067Utilizing A Genomic Sig for "BRCAness" to Eval the Efficacy of Satraplatin in Men With Met. Castration Resistant Prostate Ca
NCT04343885In Men With Metastatic Prostate Cancer, What is the Safety and Benefit of Lutetium-177 PSMA Radionuclide Treatment in Addition to Chemotherapy
NCT02582697Accelerated v's Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours
NCT03532217Neoantigen DNA Vaccine in Combination With Nivolumab/Ipilimumab and PROSTVAC in Metastatic Hormone-Sensitive Prostate Cancer
NCT04457232Prospective Exploratory Study of FAPi PET/CT in Prostate Cancer With Histopathology Validation
NCT05766371Pembrolizumab Plus 177Lu-PSMA-617 in Patients With Castration Resistant Prostate Cancer
NCT06616597Trial Targeting Gut Bacterial Androgen Production to Reverse Therapeutic Resistance to Abiraterone in Patients With Metastatic Prostate Cancer
NCT03805594177Lu-PSMA-617 and Pembrolizumab in Treating Patients With Metastatic Castration-Resistant Prostate Cancer
NCT03440554Non-contrast MR Imaging for Whole Body Cancer Detection and Characterization
NCT06126731Combination Study of Antibiotics With Enzalutamide (PROMIZE)
NCT05765500RecoverPC: Relugolix vs GnRH Agonist in Quality of Life